Itovebi

Inavolisib, the active ingredient in Itovebi, is a phosphoinositide 3-kinase (PI3K) inhibitor presented as an oral formulation for oral use. It is being investigated for the treatment of hormone receptor‑positive/HER2‑negative advanced breast cancer in adult patients.

GNH USA supplies Itovebi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Itovebi targets the PI3K/AKT signaling pathway, which is frequently dysregulated in certain breast cancers.

- Hormone receptor‑positive/HER2‑negative advanced breast cancer: aims to inhibit tumor cell proliferation and disease progression.

Adverse reactions reported with PI3Kα inhibition include both frequent and less common events.

Common Side Effects: - Hyperglycemia: elevated blood glucose levels. - Diarrhea: loose or watery stools. - Nausea: feeling of sickness. - Rash: skin redness or irritation. - Fatigue: persistent tiredness. - Elevated liver enzymes: increased ALT/AST.

Serious or Rare Side Effects: - Severe hyperglycemia requiring medical intervention. - Pneumonitis: inflammation of lung tissue. - Neutropenia: low neutrophil count increasing infection risk. - Hepatotoxicity: significant liver injury. - Colitis: inflammation of the colon. - Thromboembolic events: blood clot formation.

When prescribing Itovebi, clinicians should consider several safety measures.

- Blood glucose monitoring: check fasting glucose and HbA1c regularly. - Liver function tests: assess ALT, AST, and bilirubin before and during therapy. - Infection surveillance: watch for signs of neutropenia or opportunistic infections. - Hepatic impairment: avoid use in patients with severe liver dysfunction. - Renal impairment: adjust or monitor dosing in moderate to severe renal disease. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Inavolisib may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase drug exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antidiabetic agents (e.g., insulin, sulfonylureas): risk of severe hyperglycemia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise plasma levels. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Proton pump inhibitors: observe for altered absorption. - Herbal supplements containing St. John’s wort: may decrease drug concentration.